PAB3042
antibody from Abnova Corporation
Targeting: FGFR2
BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25
Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PAB3042 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#PAB3042, RRID:AB_1574869
- Product name
- FGFR2 polyclonal antibody
- Antibody type
- Polyclonal
- Description
- Rabbit polyclonal antibody raised against synthetic peptide of FGFR2.
- Storage
- Store at 4°C. For long term storage store at -20°C.Aliquot to avoid repeated freezing and thawing.
Submitted references Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome.
Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line.
Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM, Ittmann M, Greenberg NM, Spencer DM
Cancer research 2003 Oct 1;63(19):6237-43
Cancer research 2003 Oct 1;63(19):6237-43
P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome.
Fomenkov A, Huang YP, Topaloglu O, Brechman A, Osada M, Fomenkova T, Yuriditsky E, Trink B, Sidransky D, Ratovitski E
The Journal of biological chemistry 2003 Jun 27;278(26):23906-14
The Journal of biological chemistry 2003 Jun 27;278(26):23906-14
Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line.
Goriely A, McVean GA, Röjmyr M, Ingemarsson B, Wilkie AO
Science (New York, N.Y.) 2003 Aug 1;301(5633):643-6
Science (New York, N.Y.) 2003 Aug 1;301(5633):643-6
No comments: Submit comment
No validations: Submit validation data